HNO-Praxis Dr. med. Udo Schäfer
- Address
- Altmarkt 10A, 01067 Dresden, Germany
Birch Pollen Allergy Immunotherapy
The site focuses on immune system diseases and conducts trials for patients with moderate‑to‑severe allergic rhinitis triggered by birch pollen, aiming to evaluate new immunotherapy approaches.
- Subcutaneous cluster‑immunotherapy
- Sublingual tablet immunotherapy
- Benefit‑risk balance assessment
- Combined Symptom and Medication Score as primary outcome
HNO-Praxis Dr. med. Udo Schäfer in Dresden collaborates with international partners to improve symptom control and medication use for birch pollen allergy sufferers.
House Dust Mite Allergy Research
Clinical work at the practice includes studies on allergic rhinitis caused by house dust mites, targeting patients with persistent moderate‑to‑severe symptoms and seeking safer, effective treatments.
- Sublingual immunotherapy for house dust mite allergy
- Evaluation of long‑term safety
- Optimization of dosing schedules
- Use of the Combined Symptom and Medication Score to measure benefit
The Dresden clinic provides a specialized environment for allergy patients, contributing valuable data to global efforts in managing dust mite–induced respiratory disease.
Dose Optimization in Allergy Treatment
Across its trials, the centre investigates the most effective and well‑tolerated doses of emerging therapies for allergic rhinitis, balancing efficacy with safety.
- Determination of optimal dose levels
- Assessment of tolerability across patient groups
- Comparison of subcutaneous versus sublingual routes
- Application of the Combined Symptom and Medication Score for benefit‑risk analysis
By enrolling patients with birch pollen and house dust mite sensitivities, HNO-Praxis Dr. med. Udo Schäfer advances personalized allergy care in Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1ROXALL Medizin GmbH3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HNO-Praxis Dr. med. Udo Schäfer
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Subcutaneous Cluster-Immunotherapy with Birch Pollen Allergoid Glutaraldehyde Modified in Moderate-to-Severe Allergic Rhinitis | ROXALL Medizin GmbH | Phase IV | Not Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Betula Pollen Extract | 1 | Unknown | 2025-09-01 | 2025-09-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.